GlassScriptPhysician profile
Michelle S Craig
NPI 1568698389
$2,427.37
in general payments reported to CMS, 2019-2025
25 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,255 · 2020: $300 · 2022: $131 · 2023: $281 · 2024: $252 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $293.95 | 2019-2025 | |
| Amgen INC. | $266.52 | 2019-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $256.92 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $229.93 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $207.81 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $165.92 | 2019-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $161.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $134.14 | 2019-2023 | |
| Abbvie INC. | $96.06 | 2023-2025 | Ubrelvy |
| Sanofi Pasteur INC. | $89.00 | 2019-2024 | |
| Glaxosmithkline, LLC. | $85.16 | 2019-2023 | Arexvy |
| E.R. Squibb & Sons, L.L.C. | $60.17 | 2019-2024 | Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $57.22 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $44.45 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $37.35 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $34.20 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $32.46 | 2020-2024 | Ajovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.60 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $30.41 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $29.09 | 2023-2024 | Quviviq |
| Optinose US, INC. | $23.12 | 2023 | |
| Exact Sciences Corporation | $18.88 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.05 | 2020 | |
| Mylan Specialty L.P. | $13.94 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Craig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.